Moberg Pharma AB Announces Increase in Share Capital Following Directed Share Issue

Moberg Pharma AB Announces Increase in Share Capital Following Directed Share Issue

Moberg Pharma AB (publ) ("the Company") has announced today that the total number of common shares in the Company has increased to 47,879,854. This follows a directed share issue to investors who had committed to top guarantee undertakings in connection with the exercise of warrants of series 2023:1 (TO 2) ("the Share Issue"). The Share Issue has resulted in an increase of the number of common shares and votes in the Company by 863,333. As of July 31, 2024, the last trading day of the month, the total number of common shares and votes in the Company amounts to 47,879,854.

At the time of this press release, the Company holds 1,186,522 own common shares. For more information, please contact:
Anna Ljung, CEO, phone: 070 – 766 60 30, email: anna.ljung@mobergpharma.se
Mark Beveridge, VP Finance, phone: 076 – 805 82 88, email: mark.beveridge@mobergpharma.se

Strategic Implications and Future Prospects

The increase in share capital is a strategic move by Moberg Pharma to enhance its financial flexibility and support its growth initiatives. The Company has been focusing on the commercialization of its proprietary pharmaceuticals, particularly MOB-015, a new topical treatment for nail fungus. MOB-015 has received market approval in 13 EU countries and is sold in Sweden under the brand name Terclara® across all pharmacy chains.

Clinical phase 3 studies involving more than 800 patients indicate that MOB-015 has the potential to become the future market leader in nail fungus treatment. With commercial partnerships in place across Europe and Canada, Moberg Pharma is well-positioned to capitalize on the growing demand for effective nail fungus treatments.

Given the positive clinical data and the strategic increase in share capital, Moberg Pharma appears to be on a solid growth trajectory. The additional funds raised through the Share Issue will likely be used to further expand the market reach of MOB-015 and to support other pipeline projects.

Investment Perspective

From an investment standpoint, the directed share issue and the resulting increase in share capital are positive indicators of the Company's proactive approach to strengthening its financial base. The successful commercialization of MOB-015 and the promising clinical data suggest that Moberg Pharma is poised for significant growth. Investors should consider the potential for increased market share and revenue growth as MOB-015 gains traction in the market.

However, as with any investment, it is essential to consider the risks involved. The pharmaceutical industry is highly competitive, and the success of new treatments can be influenced by various factors, including regulatory approvals, market acceptance, and competitive products.

In conclusion, the strategic increase in share capital and the positive outlook for MOB-015 make Moberg Pharma an attractive investment opportunity. Investors should keep an eye on the Company's progress and consider the potential for long-term growth in their investment decisions.